ConductScience.org, home

Paper36650528

An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells.

Yoshida M and 5 others. Cancer Cell Int, 2023. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells. Papers, record 36650528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36650528

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells.
PubMed
Journal
Cancer Cell Int
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
1.24
iCite
Revised in PubMed
2023-01-20
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yoshida MMisa
2Oda CChihiro
3Mishima KKeishiro
4Tsuji IItsuki
5Obika SSatoshihttps://orcid.org/0000-0002-6842-6812
6Shimojo MMasahitohttps://orcid.org/0000-0003-1859-4444

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
JP22am0401003Japan Agency for Medical Research and DevelopmentPubMed
22K07230Japan Society for the Promotion of SciencePubMed

Source PubMed

Download CSV of grants

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133621242Silencing of SRRM4 suppresses microexon inclusion and promotes tumor growth across cancers.PLoS Biol2021https://conductscience.org/library/papers/33621242PubMed
233482121Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.Cancer Cell2021https://conductscience.org/library/papers/33482121PubMed
331912902Cancer statistics, 2020.CA Cancer J Clin2020https://conductscience.org/library/papers/31912902PubMed
42985258Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.Cancer Res1985https://conductscience.org/library/papers/2985258PubMed
530926931Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.Nat Rev Cancer2019https://conductscience.org/library/papers/30926931PubMed
629240946Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Nucleic Acids Res2018https://conductscience.org/library/papers/29240946PubMed
729077690Small-cell lung cancer: what we know, what we need to know and the path forward.Nat Rev Cancer2017https://conductscience.org/library/papers/29077690PubMed
816265346Neuronal characteristics of small-cell lung cancer.Br J Cancer2005https://conductscience.org/library/papers/16265346PubMed
931110284A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer.Sci Rep2019https://conductscience.org/library/papers/31110284PubMed
1030987806Intratumoral Heterogeneity: More Than Just Mutations.Trends Cell Biol2019https://conductscience.org/library/papers/30987806PubMed
1120548947The transcription factor REST is lost in aggressive breast cancer.PLoS Genet2010https://conductscience.org/library/papers/20548947PubMed
1233574607Intratumoral heterogeneity in cancer progression and response to immunotherapy.Nat Med2021https://conductscience.org/library/papers/33574607PubMed
1320011975Genome-wide identification of target genes repressed by the zinc finger transcription factor REST/NRSF in the HEK 293 cell line.Acta Biochim Biophys Sin (Shanghai)2009https://conductscience.org/library/papers/20011975PubMed
1431036929Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.Nat Biotechnol2019https://conductscience.org/library/papers/31036929PubMed
1516139198Transcriptional regulation: cancer, neurons and the REST.Curr Biol2005https://conductscience.org/library/papers/16139198PubMed
1627452466ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.Cell Rep2016https://conductscience.org/library/papers/27452466PubMed
1728089889MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Cancer Cell2017https://conductscience.org/library/papers/28089889PubMed
1832403054Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.Neoplasia2020https://conductscience.org/library/papers/32403054PubMed
1927180064SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.Eur Urol2017https://conductscience.org/library/papers/27180064PubMed
2031525487Clinical features of neuroendocrine prostate cancer.Eur J Cancer2019https://conductscience.org/library/papers/31525487PubMed

See all 46 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
40746825New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.Research (Wash D C)2025https://conductscience.org/library/papers/40746825PubMed
40133523Multi-center study: ultrasound-based deep learning features for predicting Ki-67 expression in breast cancer.Sci Rep2025https://conductscience.org/library/papers/40133523PubMed
39377066Splice-switching antisense oligonucleotide controlling tumor suppressor REST is a novel therapeutic medicine for neuroendocrine cancer.Mol Ther Nucleic Acids2024https://conductscience.org/library/papers/39377066PubMed
39304746Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer.Br J Cancer2024https://conductscience.org/library/papers/39304746PubMed
38658776Alternative splicing in prostate cancer progression and therapeutic resistance.Oncogene2024https://conductscience.org/library/papers/38658776PubMed
38621757A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides.Nucleic Acids Res2024https://conductscience.org/library/papers/38621757PubMed
37892159REST Is Not Resting: REST/NRSF in Health and Disease.Biomolecules2023https://conductscience.org/library/papers/37892159PubMed
37761978Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Int J Mol Sci2023https://conductscience.org/library/papers/37761978PubMed
37736898Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment.Noncoding RNA2023https://conductscience.org/library/papers/37736898PubMed
37662844Nucleic acid-based therapeutics for the treatment of central nervous system disorders.Front Genet2023https://conductscience.org/library/papers/37662844PubMed
37514088Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy.Pharmaceutics2023https://conductscience.org/library/papers/37514088PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CASP7840PubTator's text mininghttps://conductscience.org/library/genes/840NCBI Gene
MBL3P50639PubTator's text mininghttps://conductscience.org/library/genes/50639NCBI Gene
POTEF728378PubTator's text mininghttps://conductscience.org/library/genes/728378NCBI Gene
REST5978PubTator's text mininghttps://conductscience.org/library/genes/5978NCBI Gene
SRRM484530PubTator's text mininghttps://conductscience.org/library/genes/84530NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36650528

GET https://conductscience.org/api/papers/v1/36650528/references?page=2